Search Result

Results for "

Stearoyl-CoA

" in MedChemExpress (MCE) Product Catalog:

By Targets:	Stearoyl-CoA Desaturase (SCD) (25) Apoptosis (3) Autophagy (1) Bacterial (2) Biochemical Assay Reagents (2) DNA/RNA Synthesis (1) Drug Intermediate (1) Endogenous Metabolite (3) Fatty Acid Synthase (FASN) (2) Glutathione Peroxidase (1) Influenza Virus (3) Interleukin Related (1) Isotope-Labeled Compounds (2) LDLR (1) Lipase (1) mTOR (1) NF-κB (1) PPAR (1) Reactive Oxygen Species (ROS) (1) Reference Standards (2) SOD (1) TNF Receptor (1)
By Research Areas:	Cancer (12) Infection (2) Inflammation/Immunology (4) Metabolic Disease (16) Neurological Disease (1)

By Targets:

Stearoyl-CoA Desaturase (SCD) (25)

Apoptosis (3)

Autophagy (1)

Bacterial (2)

Biochemical Assay Reagents (2)

DNA/RNA Synthesis (1)

Drug Intermediate (1)

Endogenous Metabolite (3)

Fatty Acid Synthase (FASN) (2)

Glutathione Peroxidase (1)

Influenza Virus (3)

Interleukin Related (1)

Isotope-Labeled Compounds (2)

LDLR (1)

Lipase (1)

mTOR (1)

NF-κB (1)

PPAR (1)

Reactive Oxygen Species (ROS) (1)

Reference Standards (2)

SOD (1)

TNF Receptor (1)

By Research Areas:

Cancer (12)

Infection (2)

Inflammation/Immunology (4)

Metabolic Disease (16)

Neurological Disease (1)

Inhibitors & Agonists

Bibliothèques de criblage

Biochemical Assay Reagents

Natural
Products

Protéines recombinantes

Isotope-Labeled Compounds

Targets Recommended: Stearoyl-CoA Desaturase (SCD)

Cat. No.	Nom du produit	Target	Áreas de investigación	Chemical Structure

HY-50709

A939572 Maximum Cited Publications 40 Publications Verification	Stearoyl-CoA Desaturase (SCD)	Cancer
A939572 is a potent, and orally bioavailable stearoyl-CoA desaturase1 (SCD1) inhibitor with IC₅₀ values of <4 nM and 37 nM for mSCD1 and hSCD1, respectively.

HY-15823

CAY10566 15+ Cited Publications	Stearoyl-CoA Desaturase (SCD)	Cancer
CAY10566 is a potent, orally bioavailable and selective stearoyl-CoA desaturase1 (SCD1) inhibitor with IC₅₀s of 4.5 and 26 nM in mouse and human enzymatic assays, respectively. CAY10566 also shows excellent cellular activity in blocking the conversion of saturated long-chain fatty acid-CoAs (LCFA-CoAs) to monounsaturated LCFA-CoAs in HepG2 cells (IC₅₀=7.9 nM or 6.8 nM) .

HY-15700

PluriSIn 1 4 Publications Verification NSC 14613	Stearoyl-CoA Desaturase (SCD) Apoptosis	Cancer
PluriSIn 1 (NSC 14613) is an inhibitor of stearoyl-coA desaturase (SCD), and is a pluripotent cell-specific inhibitor.

HY-155033

SSI-4	Stearoyl-CoA Desaturase (SCD) DNA/RNA Synthesis Apoptosis Autophagy mTOR Influenza Virus	Metabolic Disease Inflammation/Immunology Cancer
SSI-4 is an orally active stearoyl-CoA desaturase (SCD1) inhibitor with an EC₅₀ of 1.9 nM against mouse SCD1. SSI-4 blocks the conversion of saturated fatty acids to monounsaturated fatty acids, reducing the production of oleic acid and palmitoleic acid. SSI-4 induces lipid peroxidation, endoplasmic reticulum stress, DNA damage and activates apoptotic mechanisms. SSI-4 inhibits mTORC1 activity, suppresses B cell proliferation and antibody production, and induces autophagy. SSI-4 is applicable to research on cancers such as acute myeloid leukemia and renal cell carcinoma, as well as influenza infections .

HY-19762

GSK1940029 3 Publications Verification SCD inhibitor 1	Stearoyl-CoA Desaturase (SCD)	Cancer
GSK1940029 (SCD inhibitor 1) is a stearoyl-coa desaturase (SCD) inhibitor extracted from patent WO/2009060053 A1, compound example 16.

HY-13070

MK-8245 4 Publications Verification	Stearoyl-CoA Desaturase (SCD)	Metabolic Disease
MK-8245 is a potent, liver-targeted stearoyl-CoA desaturase (SCD) inhibitor, with IC₅₀s of 1 nM for human SCD1 and 3 nM for both rat SCD1 and mouse SCD1, with antidiabetic and antidyslipidemic efficacy .

HY-127143

Sterculic acid	Stearoyl-CoA Desaturase (SCD)	Inflammation/Immunology
Sterculic acid is a stearoyl-CoA desaturase-1 (SCD1) inhibitor. Sterculic acid specifically inhibits the delta-9 desaturase (Δ9D) activity with an IC₅₀ value of 0.9 μM .

HY-N6807

Elemicin 1 Publications Verification	Stearoyl-CoA Desaturase (SCD) Influenza Virus Bacterial	Infection Cancer
Elemicin is an orally active alkenylbenzene widely distributed in many herbs and spices. Elemicin inhibits Stearoyl-CoA Desaturase 1 (SCD1) by metabolic activation. Elemicin has anti-influenza activities, antimicrobial, antioxidant, and antiviral activities. Elemicin and its reactive metabolite of 1′-Hydroxyelemicin can induce hepatotoxicity .

HY-15822

MF-438 5+ Cited Publications	Stearoyl-CoA Desaturase (SCD)	Metabolic Disease
MF-438 is a potent and orally bioavailable stearoyl-CoA desaturase 1 (SCD1) inhibitor with an IC₅₀ of 2.3 nM for rSCD1 .

HY-141525

SCD1 inhibitor-4	Stearoyl-CoA Desaturase (SCD)	Metabolic Disease
SCD1 inhibitor-4 is a potent, orally active stearoylCoA desaturase-1 (SCD1) inhibitor. SCD1 inhibitor-4 can be used for the research of diabetes .

HY-124346

T-3364366 1 Publications Verification	Stearoyl-CoA Desaturase (SCD)	Metabolic Disease
T-3364366 is a reversible, slow-binding, thienopyrimidinone delta-5 desaturase (D5D) inhibitor with IC₅₀s of 1.9 nM and 2.1 nM in HepG2 and RLN-10 cells, respectively. T-3364366 exhibits potent D5D (IC₅₀0=19 nM) inhibitory activity and excellent selectivity away from delta-6 desaturase (D6D, IC₅₀=6200 nM) and delta-9 desaturase (stearoyl-CoA desaturase, SCD,₅₀ >10000 nM) in the enzymatic activity assay .

HY-116538

(10E,12Z)-Octadeca-10,12-dienoic acid 1 Publications Verification trans-10,cis-12 CLA2	Endogenous Metabolite PPAR NF-κB Stearoyl-CoA Desaturase (SCD) Lipase	Metabolic Disease Inflammation/Immunology Cancer
(10E,12Z)-Octadeca-10,12-dienoic acid (trans-10,cis-12 CLA2) is an orally active PPARα activator and inhibits adipocyte differentiation. (10E,12Z)-Octadeca-10,12-dienoic acid and its downstream metabolites have various antioxidant and antitumor activities. (10E,12Z)-Octadeca-10,12-dienoic acid can induce proinflammatory cytokines and chemokines, which would lead to decreased adipogenesis and insulin resistance in adipose tissue. (10E,12Z)-Octadeca-10,12-dienoic acid can affect many aspects of milk fat synthesis. (10E,12Z)-Octadeca-10,12-dienoic acid reduces expression of lipogenic enzymes and inhibits the desaturation of fatty acids. (10E,12Z)-Octadeca-10,12-dienoic acid can reduce lipoprotein lipase (LPL) activity in cultured 3T3-L1 adipocytes and enhance triacylglycerol release from these cells. (10E,12Z)-Octadeca-10,12-dienoic acid decreases the expression of *hepatic stearoyl-CoA* desatyrase mRNA in mice. (10E,12Z)-Octadeca-10,12-dienoic acid is associated with changes in mucosal NF-κB and Cyclin D1** protein levels in mice .

HY-112812

SCD1 inhibitor-1	Stearoyl-CoA Desaturase (SCD)	Metabolic Disease
SCD1 inhibitor-1 (Compound 48) is an orally active and liver-selective inhibitor of stearoyl-CoA desaturase 1 (SCD1) with an IC₅₀ of 8.8 nM for recombinant human SCD1 enzyme. SCD1 inhibitor-1 can be used in the study of diseases such as diabetes, hepatic steatosis and obesity .

HY-134423S

Stearoyl coenzyme A-13C18 lithium	Isotope-Labeled Compounds	Others
Stearoyl coenzyme A- ¹³C₁₈ (lithium) is the ¹³C labeled Stearoyl coenzyme A lithium . Stearoyl coenzyme A (Stearoyl-CoA) lithium is an active compound that can be used as a substrate for the determination of stearoyl-Coenzyme desaturase in microsomes .

HY-34054

2,4-Dichloro-5-nitropyridine	Drug Intermediate	Others
2,4-Dichloro-5-nitropyridine is a pyridine derivative, which can be used as a precursor to synthesize polyfluorinated pyrrolidine derivatives ^[3][4].

HY-100249

XEN723	Stearoyl-CoA Desaturase (SCD)	Metabolic Disease
XEN723 is a novel and potent thiazolylimidazolidinone inhibitor of Stearoyl-CoA Desaturase (SCD1) with IC₅₀s of 45 and 524 nM in mouse and HepG2 cell, respectively.

HY-13077

MK-8245 Trifluoroacetate 4 Publications Verification	Stearoyl-CoA Desaturase (SCD)	Metabolic Disease
MK-8245 trifluoroacetate is a liver-targeting inhibitor of stearoyl-CoA desaturase (SCD) with IC50 of 1 nM for human SCD1 and 3 nM for both rat SCD1 and mouse SCD1, with anti-diabetic and anti-dyslipidemic efficacy.

HY-E70265

18:0 Coenzyme A triammonium	Fatty Acid Synthase (FASN) Endogenous Metabolite	Metabolic Disease
18:0 Coenzyme A (triammonium) is a preferred substrate of stearoyl-CoA desaturases (SCDs) .

HY-124084

SW203668	Stearoyl-CoA Desaturase (SCD)	Cancer
SW203668 is an irreversible stearoyl CoA desaturase (SCD) inhibitor with an IC₅₀ of 54 nM. SW203668 covalently binds and inhibits SCD, depletes unsaturated fatty acids, and triggers cell death in sensitive cells. SW203668 requires demethylation by CYP4F11 to form its active SCD-inhibiting form; differential CYP4F11 expression drives selective cytotoxicity. SW203668 exerts cytotoxicity toward CYP4F11-expressing non-small cell lung cancer (NSCLC) cells and spares CYP4F11-lacking NSCLC cells. SW203668 inhibits tumor growth in immunodeficient mice bearing CYP4F11-expressing NSCLC xenografts and spares mouse skin sebocytes. SW203668 can be used for the research of non-small cell lung cancer .

HY-134423

Stearoyl coenzyme A lithium Stearoyl-CoA lithium	Biochemical Assay Reagents	Others
Stearoyl coenzyme A (Stearoyl-CoA) lithium is an active compound that can be used as a substrate for the determination of stearoyl-Coenzyme desaturase in microsomes .

HY-11034

CVT-12012	Stearoyl-CoA Desaturase (SCD)	Metabolic Disease
CVT-12012 is a potent and orally bioavailable stearoyl-coA desaturase (SCD) inhibitor, with IC₅₀s of 38 nM, 6.1 nM for rat microsomal and human HEPG2, respectively.

HY-124751

YTX-465	Stearoyl-CoA Desaturase (SCD)	Neurological Disease
YTX-465 is a stearoyl-CoA desaturase (Ole1/SCD) inhibitor. YTX-465 inhibits Ole1 and SCD1 with IC₅₀s of 0.039 μM and 30.4 μM, respectively. YTX-465 can be used in the research of Parkinson’s disease and other synucleinopathies .

HY-176274

FASN/SCD-IN-1	Fatty Acid Synthase (FASN) Stearoyl-CoA Desaturase (SCD) Reactive Oxygen Species (ROS) Interleukin Related TNF Receptor SOD LDLR Glutathione Peroxidase	Metabolic Disease Inflammation/Immunology
FASN/SCD-IN-1 is a Silybin (HY-N0779A) derivative, an orally active inhibitor of Fatty Acid Synthase (FASN)/Stearoyl-CoA Desaturase (SCD). FASN/SCD-IN-1 has shown in vitro activity in inhibiting lipid deposition, reducing FASN and SCD transcriptional levels, and exhibiting antioxidant, anti-inflammatory, and anti-fibrotic activities. FASN/SCD-IN-1 has demonstrated significant hepatoprotective effects in a rat model of acute liver injury. FASN/SCD-IN-1 ameliorates the pathological features of MASH liver, including steatosis, inflammation, and fibrosis in a mouse model of myeloproliferative steatohepatitis (MASH). FASN/SCD-IN-1 can be used to study MASH .

HY-CE01870

S-Octadecenoate-CoA Stearoyl-CoA; Stearoyl-coenzyme A	Biochemical Assay Reagents	Metabolic Disease
S-Octadecenoate-CoA (Stearoyl-CoA; Stearoyl-coenzyme A) is a coenzyme A derivative .

HY-N6807R

Elemicin (Standard)	Reference Standards Stearoyl-CoA Desaturase (SCD) Influenza Virus Bacterial	Infection Cancer
Elemicin is an orally active alkenylbenzene widely distributed in many herbs and spices. Elemicin inhibits Stearoyl-CoA Desaturase 1 (SCD1) by metabolic activation. Elemicin has anti-influenza activities, antimicrobial, antioxidant, and antiviral activities. Elemicin and its reactive metabolite of 1′-Hydroxyelemicin can induce hepatotoxicity .

HY-50709R

A939572 (Standard)	Stearoyl-CoA Desaturase (SCD)	Cancer
A939572 (Standard) is the analytical standard of A939572. This product is intended for research and analytical applications. A939572 is a potent, and orally bioavailable stearoyl-CoA desaturase1 (SCD1) inhibitor with IC50 values of <4 nM and 37 nM for mSCD1 and hSCD1, respectively.

HY-E70275

Nonadecanoyl-CoA Coenzyme A,S-nonadecanoate	Endogenous Metabolite	Metabolic Disease
Nonadecanoyl-CoA is a derivative of nonadecanoic acid's coenzyme A, which can inhibit the activity of *stearoyl-CoA* .

HY-114527

TPMP-I-2	Apoptosis Stearoyl-CoA Desaturase (SCD)	Cancer
TPMP-I-2 is an anticancer agent that induces cancer cell lines Apoptosis and decreases protein levels of stearoyl-CoA desaturase. TPMP-I-2 prolongs the survival time of nude rats in a simulated micrometastatic cervical cancer model and reduces tumor growth in a breast cancer model in nude mice combined with immunotoxins .

HY-124084A

SW203668 TFA	Stearoyl-CoA Desaturase (SCD)	Cancer
SW203668 TFA is an irreversible stearoyl CoA desaturase (SCD) inhibitor with an IC₅₀ of 54 nM. SW203668 TFA covalently binds and inhibits SCD, depletes unsaturated fatty acids, and triggers cell death in sensitive cells. SW203668 TFA requires demethylation by CYP4F11 to form its active SCD-inhibiting form; differential CYP4F11 expression drives selective cytotoxicity. SW203668 TFA exerts cytotoxicity toward CYP4F11-expressing non-small cell lung cancer (NSCLC) cells and spares CYP4F11-lacking NSCLC cells. SW203668 TFA inhibits tumor growth in immunodeficient mice bearing CYP4F11-expressing NSCLC xenografts and spares mouse skin sebocytes. SW203668 TFA can be used for the research of non-small cell lung cancer .

HY-114184

MK-8245 analog	Stearoyl-CoA Desaturase (SCD)	Metabolic Disease
MK-8245 analog (compound 6) is a potent stearoyl-CoA desaturase (SCD) inhibitor with an IC₅₀ of 7 nM for rat SCD. MK-8245 analog has antidiabetic and antidyslipidemic effects .

HY-W013627S

trans,trans-2,4-Decadienal-d4	Isotope-Labeled Compounds	Others
trans,trans-2,4-Decadienal-d₄ is deuterated labeled trans,trans-2,4-Decadienal (HY-W013627). trans,trans-2,4-Decadienal is a lipid peroxidation product of linolieic acid .

HY-100249R

XEN723 (Standard)	Stearoyl-CoA Desaturase (SCD) Reference Standards	Metabolic Disease
XEN723 (Standard) is the analytical standard of XEN723 (HY-100249). This product is intended for research and analytical applications. XEN723 is a novel and potent thiazolylimidazolidinone inhibitor of Stearoyl-CoA Desaturase (SCD1) with IC50s of 45 and 524 nM in mouse and HepG2 cell, respectively.

Cat. No.	Nom du produit

HY-L087

Anti-Obesity Compound Library	3,558 compounds
Obesity is widely recognized as the largest and fastest growing public health problem and is associated with numerous chronic disorders including osteoarthritis, obstructive sleep apnea, gallstones, fatty liver disease, reproductive and gastrointestinal cancers, dyslipidemia, hypertension, type 2 diabetes, heart failure, coronary artery disease, stroke, etc. Although obesity has long been associated with serious health issues, it has only recently been regarded as a disease in the sense of being a specific target for medical therapy. Obesity may be viewed as the dysregulation of two physiological functions, appetite regulation and energy metabolism, which combine to create disordered energy balance. Consequently, developing obesity treatments that target novel pathways is a growing focus for both biopharmaceutical industries. MCE Anti-Obesity Compound Library owns a unique collection of 3,558 compounds, which mainly target signaling pathway of controlling appetite, fatty acid metabolism and energy expenditure, etc. This library is a useful tool for discovery anti-obesity drugs.

Anti-Obesity Compound Library

3,558 compounds

Obesity is widely recognized as the largest and fastest growing public health problem and is associated with numerous chronic disorders including osteoarthritis, obstructive sleep apnea, gallstones, fatty liver disease, reproductive and gastrointestinal cancers, dyslipidemia, hypertension, type 2 diabetes, heart failure, coronary artery disease, stroke, etc. Although obesity has long been associated with serious health issues, it has only recently been regarded as a disease in the sense of being a specific target for medical therapy. Obesity may be viewed as the dysregulation of two physiological functions, appetite regulation and energy metabolism, which combine to create disordered energy balance. Consequently, developing obesity treatments that target novel pathways is a growing focus for both biopharmaceutical industries.

MCE Anti-Obesity Compound Library owns a unique collection of 3,558 compounds, which mainly target signaling pathway of controlling appetite, fatty acid metabolism and energy expenditure, etc. This library is a useful tool for discovery anti-obesity drugs.

Cat. No.	Nom du produit	Type